哌拉西林/他唑巴坦治疗老年社区获得性肺炎的调查分析

Evaluation of efficacy of piperacillin/tazobactam for aged patients with community-acquired pneumonia

目的观察哌拉西林/他唑巴坦在老年社区获得性肺炎患者临床治疗中的疗效及安全性。方法从2009年10月-2010年12月96例老年社区获得性肺炎住院患者,按不同配方制剂随机分为观察组和对照组,观察组以哌拉西林/他唑巴坦治疗4∶1治疗,5.0g静脉滴注,2次/d;对照组以哌拉西林/他唑巴坦8∶1治疗,6.75g静脉滴注,2～3次/d,疗程均为7～12d,疗程结束后观察临床疗效。结果治疗组和对照组有效率分别为93.8%和91.7%,细菌清除率分别为83.3%和78.3%,两组疗效比较差异均无统计学意义。结论哌拉西林/他唑巴坦4∶1具有与哌拉西林/他唑巴坦8∶1对老年社区获得性肺炎住院患者相似的治疗作用,可作为早期痰培养加药敏试验检查结果之前的经验性治疗用药。

OBJECTIVE To investigate the efficacy and safety of piperacillin/tazobactam in the treatment of aged patients with community acquired pneumonia.METHODS A total of 96 hospitalized aged patients with community-acquired pneumonia from Oct.2009 to Dec.2010 were randomly divided into the intervention group（48 cases） and the control group（48 cases）.The intervention group received piperacillin/tazobactam 4∶1（5.0g） intravenously,twice a day for 7~12 days;the control group received piperacillin/tazobactam 8∶1（6.75g）intravenously,twice or three times a day for 7~12 days.The clinical therapeutic effect was compared at end point of therapy.RESULTS The effective rate was 93.8% in the intervention group and the effective rate was 91.7% in the control group;bacterial clearance rates were 83.3% and 78.3% respectively.There was no significant difference between the two groups（P0.05）.CONCLUSION Piperacillin/tazobactam 4∶1 is shown to be the same safe and effective as piperacillin/ tazobactam 8∶1 in the treatment of elderly community-acquired pneumonia in hospitalized patients,and hence is worthy of being recommended in early clinical empirical practice before the result of bacterial culture and drug susceptibility tests are gained.